Recurrent Ascites in a Patient With Low-grade Astrocytoma and Ventriculo-Peritoneal Shunt Treated With the Multikinase Inhibitor Sorafenib

This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial. Laboratory analysis of the peritoneal fluid showed no elevation of protein content and no evidence of underlying infection or tumor dissemination. This report highlights ascites as a previously unrecognized adverse reaction to sorafenib in a patient with a ventriculo-peritoneal shunt. We conclude that such patients should be closely monitored for this complication when treated with sorafenib.

[1]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[2]  L. Tye,et al.  A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer , 2011, Cancer Chemotherapy and Pharmacology.

[3]  M. Friedlander,et al.  A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. , 2010, Gynecologic oncology.

[4]  Y. Bang,et al.  Phase II study of sunitinib as second-line treatment for advanced gastric cancer , 2010, Investigational New Drugs.

[5]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[6]  S. Steinberg,et al.  A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer , 2007, Cancer.

[7]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[8]  D. Bodurka,et al.  Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. , 2006, Gynecologic oncology.

[9]  Michele H Johnson,et al.  Sterile ascites from a ventriculoperitoneal shunt: a case report and review of the literature , 2006, Child's Nervous System.

[10]  Anil K Sood,et al.  Vascular Endothelial Growth Factor Trap Combined with Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer Model , 2005, Clinical Cancer Research.

[11]  T. Tomita,et al.  Post-shunt ascites in infants with optic chiasmal hypothalamic astrocytoma: role of ventricular gallbladder shunt , 2005, Child's Nervous System.

[12]  K. Lackey,et al.  The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. , 2001, Molecular cancer therapeutics.

[13]  E. Smit,et al.  Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. , 2000, The oncologist.

[14]  A. Shuper,et al.  Optic chiasm glioma, electrolyte abnormalities, nonobstructive hydrocephalus and ascites. , 1997, Medical and pediatric oncology.

[15]  G. Criscuolo,et al.  Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. , 1995, Journal of neurosurgery.

[16]  J. Mealey,et al.  Cerebrospinal fluid ascites complicating ventriculoperitoneal shunting , 1984 .

[17]  M. J. Weidmann.  Ascites from a ventriculoperitoneal shunt. , 1975, Journal of neurosurgery.

[18]  R. Ames.  Ventriculo-peritoneal shunts in the management of hydrocephalus. , 1967, Journal of neurosurgery.

[19]  M. Berger,et al.  Childhood optic pathway tumors associated with ascites following ventriculoperitoneal shunt placement. , 1994, Pediatric neurosurgery.

[20]  J. Kalsbeck,et al.  Cerebrospinal fluid ascites complicating ventriculoperitoneal shunting. Report of four cases. , 1984, Journal of neurosurgery.